MADD Inhibitors
MADD inhibitors are a class of chemical compounds that target the MAPK activating death domain protein, which is often abbreviated as MADD. MADD is a signaling adaptor protein that plays a role in the regulation of various cellular processes, including proliferation, differentiation, and apoptosis. The protein interacts with a range of other molecules within the cell, participating in complex signaling pathways that are crucial for maintaining cellular homeostasis. Inhibitors of MADD are designed to modulate the activity of this protein, effectively influencing the downstream signaling events that it controls. By binding to MADD or its associated partners, these inhibitors can alter the typical outcome of MADD-involved signaling cascades.
The structure and function of MADD inhibitors are diverse, reflecting the complexity of the pathways in which the MADD protein is involved. These compounds may vary widely in their molecular composition, ranging from small organic molecules to larger, more complex structures. The mechanisms by which MADD inhibitors exert their effects also differ, with some blocking the interaction between MADD and its binding partners, while others might prevent downstream signaling by affecting the conformation of the MADD protein itself. In addition, these inhibitors may exhibit varying degrees of specificity and selectivity for MADD, with some compounds showing a high affinity for their target, and others affecting a broader range of proteins within the signaling network.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An anthrapyrazolone inhibitor of c-Jun N-terminal kinase (JNK), which is upstream of MAPK signaling pathways. By inhibiting JNK, SP600125 can suppress the activation of MAPKs that may be regulated by MADD. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK, which works similarly to U0126, thereby preventing the activation of MAPK/ERK pathway components that could be influenced by MADD. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A pyridinyl imidazole inhibitor of p38 MAP kinase, which is another kinase that may interact with the pathways regulated by MADD. Inhibition of p38 can disrupt signaling processes involving MADD. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), which can affect the AKT pathway that indirectly modulates MAPK pathway activity, possibly impacting MADD's role in signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor, similar to LY294002, which can alter AKT pathway signaling and thus influence MAPK pathway components associated with MADD function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can disrupt the mTOR signaling pathway, which has downstream effects on the MAPK/ERK pathway, potentially affecting MADD-related signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A kinase inhibitor that targets multiple receptors, such as VEGFR and PDGFR, and can inhibit RAF kinases, thereby disrupting MAPK/ERK pathway signaling at a level that may involve MADD. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
A multi-targeted receptor tyrosine kinase inhibitor that can inhibit signaling pathways upstream of MAPK, thus potentially influencing MADD-related processes. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
An inhibitor of MEK1 and MEK2, offering a mechanism of action similar to that of U0126 and PD98059, affecting MAPK/ERK signaling related to MADD. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Another selective inhibitor of MEK1/2, which can suppress the activation of the MAPK/ERK pathway, potentially affecting signaling processes that involve MADD. | ||||||